Category: Uncategorized

Laboratorios Farmacéuticos ROVI, S.A. (hereinafter “ROVI”), a specialised pan-European biopharmaceutical company engaged in research, has completed the work on its new plant in Escúzar (Granada) with the expansion of the existing facilities by 1,620 square metres and the inclusion of a new sodium heparin production line. With this operation, in which ROVI has invested an additional 11 million euros, the company continues to advance in the vertical integration strategy for its low-molecular-weight heparin (hereinafter, “LMWH”) franchise. Furthermore, the expansion of the Escúzar facilities is expected to create 15 new jobs, which would raise the total number of employees at these facilities to around 60.

Miguel Ángel Ortega Sánchez, ROVI’s Industrial Manager, said: “At ROVI, we are very proud to announce the completion of the work to expand our new plant in Escúzar, since it reinforces our production capacity significantly and makes our position among the world leaders in the heparin market even stronger.”

Thus, the new Escúzar plant now houses two lines within the LMWH manufacturing process: the production line for the active principle of heparins, which came into operation at the end of 2023 and has a capacity of 673,000 MIU (million international units), equivalent to approximately 134.6 million syringes, and the new sodium heparin production line, with a capacity of 1,200,000 MIU of sodium heparin for 2025, equivalent to 88 million syringes, which has now received authorisation to

commence commercial activity from the Spanish Agency of Medicines and Medical Devices.

The LMWH production process consists of three purification phases: it starts by obtaining crude heparin from pig mucosa, continues with the transformation into sodium heparin (unfractionated heparin), and concludes when the low-molecular-weight heparins are obtained.

The inauguration of this new sodium heparin facility represents a further step in the vertical integration of ROVI’s LMWH production. It joins the facilities that are being constructed in Fraga (Huesca) for Glicopepton, ROVI’s joint venture with Costa Food Group and Càrniques Celrà for the first part of the production process, and the already-existing LMWH production line in Escúzar.

With this strategy, ROVI continues to reinforce the guarantee, autonomy and visibility of the production of heparins, a product classified as essential by the European Union and the World Health Organisation and also a strategic business segment for ROVI, in which the company aspires to become a global industry leader.

Clean-up team…Let’s go! The ROVI Team put on its gloves to clean up the Casa de Campo of rubbish on Saturday 15 July. Together with the Fundación Deporte y Desafío, the 15 ROVI volunteers organised themselves into teams to sweep the reclaimed area of the Manzanares River, starting at the fountain and the viewpoint of the Huerta de La Partida and continuing on to the Palacio de los Vargas.

But it wasn’t all about cleaning up, as we took the opportunity to learn a little more about the history behind both locations, while doing recycling workshops with members of the foundation. Mission accomplished!

We would like to share with you the video of the activity and encourage you to take part in the ROVI Team’s volunteering activities.

Do you have an efficient way to recycle that you would like to share with your colleagues? Any tips on how to use less electricity? Do you do any environmentally friendly activities? Submit it to THE GREEN IDEAS and enter the competition.

The competition entries will be presented to ROVI employees so that they can choose their favourite. The 3 most voted will be awarded with:

1st Prize: Gift Card 300€.
2nd Prize: Gift Card 150€.
3rd Prize: Gift Card 50€.

To enter the competition, please send an email to galvaros@rovi.es with:

• The subject of the email: NAME + GREEN IDEAS.
• Indicate your full name and contact number.
• Explain what it consists of. Send us a video telling or showing your idea. Remember to sign the Image Rights Authorisation in order to be able to share your proposal.

Deadline: 25 June

The ROVI Granada Team armed themselves with helmets and bicycles to tackle last Saturday’s bike ride with the Fundación Deporte y Desafío. During the 16-kilometre ride, the 15 ROVI volunteers were able to accompany the members of the foundation on their way to the adventure, completing the La Laguna route while enjoying the good weather and the views that accompanied them.

The starting point of the route was the Aura de la Naturaleza El Aguadero, where the volunteers were able to take the bikes provided by the foundation and set off. From there, a circular route awaited them, passing by the Ermita de la Virgen de la Cabeza (Cozvijar, Granada) and then continuing on to the Cascada del Río Dúrcal. A route with a low gradient and accessible to all participants.

Say goodbye to Diverclick. The new ROVI Discounts platform will bring more and better offers for ROVI employees.

If you are registered on the old Diverclick platform, you will have received an email where you can register on the new one. If you have accumulated money, don’t worry, as it will remain open for a while so you can spend it.

REGISTER FOR ROVI DISCOUNTS

Enter the platform by CLICKING HERE

• Go to “Create an account”. Complete the data by entering your corporate email address. If you don’t have one, enter a normal email address and enter the code: ROVI01.
• You will receive an email to complete your registration. It may take some time to arrive, depending on the registration traffic.

Take advantage of exclusive offers for ROVI employees. On the website you’ll find discounts in restaurants, supermarkets, cinemas, travel agencies, hotels, fashion, perfumery, homeware… and much more.

Effort, healthy competition and lots of laughter came together on 27 and 28 April at the ROVI Padel Tournament. A total of 42 pairs competed to see who was the best on the courts, dividing the participants into 3 categories according to their level: beginners, intermediate and advanced.

The championship took place at Club Fuencarral A La Par, where 12 padel courts were reserved to make the different phases of the tournament more dynamic. The competition started with a group stage on Saturday 27th, where only the best 4 pairs of each one would go through. On Sunday 28th the final tournament took place, where each pair fought to win their category.

WINNERS OF THE ROVI PADEL TOURNAMENT

Laboratorios Farmacéuticos ROVI announces the financial results obtained in the first quarter of 2024, that is critically important in establishing the bases for ROVI’s future growth.

The company closed the first quarter of 2024 with operating revenue of 151.2 million euros, EBITDA of 25.9 million euros and a net profit of 15.0 million.

Revenue from the CDMO business decreased 48% to 50.1 million, mainly due to lower revenue from manufacture of the COVID-19 vaccine in comparison with the first quarter of 2023, when ROVI booked higher revenue from production of the ”pandemic” vaccine and lower revenue related to the activities to prepare the plant for production of the vaccine under the agreement with Moderna.

Sales of the heparin franchise (low-molecular-weight heparins and other heparins) fell 8% to 56.3 million euros in the first quarter of 2024, due to a lower volume of orders from partners, since they held a higher level of stocks of these products from the fourth quarter of 2023. Sales of Risperidone ISM® evolved positively upwards to 5.4 million euros in the first quarter of the year, multiplying the 2023 first quarter figure by 2.4. In March 2024, ROVI received FDA approval for the marketing of Risperidone ISM® in the United States to treat schizophrenia in adults.

This is a historic milestone for the company as this is the first of its own product to receive marketing authorisation in the United States, the most important market worldwide for long-acting injectable antipsychotics.

Additionally, in the first quarter of 2024, ROVI approved marketing authorisation for this product in Canada and Australia. Research and development expenses rose 17% to 6.1 million euros and were mainly related to the development of phase 1 of Letrozole LEBE and the development of phase 1 of the new formulation of Risperidone ISM® for a three-monthly injection. Additionally, we were able to decrease operating expenses, excluding R&D and employee benefit expenses, by 11% as the result of an efficient cost containment policy.

Regarding guidance for 2024, ROVI expects its operating revenue to decrease by a mid-single-digit percentage, although this guidance considers certain factors that could affect the estimates but are difficult to specify at the present time. ROVI is in a new phase of growth and has confidence in the development potential of its specialty pharmaceuticals division and its CDMO business.

Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical company that specialises and engages in the research, development, contract manufacturing and licensing of small molecules and biological medicines, has
announced today that its subsidiary ROVI Pharma Industrial Services, S.A.U. (hereinafter “ROIS”) has entered into an agreement to support the manufacture of pre-filled syringes for a global pharmaceutical company.

Under the terms of the agreement, ROIS will provide a high-speed production line at the ROIS’ San Sebastián de los Reyes facility in Madrid, with an estimated annual capacity of 100 million units. The agreement includes the technology transfer for aseptic filling and has a commercial production term of five years subject to the terms of the agreement, beginning on the date of manufacture of the first commercial lot. After the technology transfer and regulatory approval, commercial production is expected to commence in 2026. As from 2027, which is expected to be the first full recurrent manufacturing year, the ROVI´s Group CDMO division expects to have a positive revenues increase impact ranging between 20% and 45% over 2023 sales.

ROIS is well-equipped to support the production of pre-filled syringes given its deep expertise in the current good manufacturing practice (cGMP) production of sterile injectable products across both vials and pre-filled syringes.

Juan López-Belmonte Encina, Chairman and Chief Executive Officer of ROVI, said: “We are delighted to be able to support in the manufacture of medicine that is able to prolong the life of millions of people. Our proven experience in the manufacture of high-valued-added injectables and the expansion of our production capacities have positioned us to help meet the rapidly growing demand, which requires a high degree of technological capability.”

Sign up for the 1st Paddle Tennis Tournament just for ROVI employees. Form a couple. It can be mixed, male or female.

Date: 27th and 28th of April from 16:00 to 21:00

Place: Club Fuencarral A LA PAR

Category:

• Beginners
• Medium
• Advanced

Register HERE

Deadline: 5 April at 17:30